Clinical Trial

Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Study acronym: CSPAC-48
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.
Trial Details
NCT Number NCT06916975
Lead Sponsor Jin Xu
Conditions Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Enrollment 46 participants
Start Date 2025-04-15
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-08